Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

J A Vaz

Showing results (1-10 of 8) with videos related to

Pageof 1
Sort By:
Diabetes, Obesity & Metabolism|May 23, 2008
Biphasic insulin aspart 30 treatment improves glycaemic control in patients with type 2 diabetes in a clinical practice setting: Chinese PRESENT studyY Gao, X H Guo, J A Vaz, et al.
Diabetes, Obesity & Metabolism|May 16, 2008
Biphasic insulin aspart 30 in the treatment of elderly patients with type 2 diabetes: a subgroup analysis of the PRESENT Korea NovoMixstudyH C Jang, S R Lee, J A Vaz
The Journal of the Association of Physicians of India|March 7, 2001
Clinical relevance of reduced bioavailability of rifampicinA D Bhatt, J A Vaz, K A Padgaonkar
Diabetes, Obesity & Metabolism|November 18, 2003
Twice daily biphasic insulin aspart improves postprandial glycaemic control more effectively than twice daily NPH insulin, with low risk of hypoglycaemia, in patients with type 2 diabetesJ S Christiansen, J A Vaz, Z Metelko, et al.
Diabetes, Obesity & Metabolism|June 27, 2007
Adding biphasic insulin aspart 30 once or twice daily is more efficacious than optimizing oral antidiabetic treatment in patients with type 2 diabetesW M W Bebakar, C C Chow, K A Kadir, et al.
Current Medical Research and Opinion|January 25, 2008
Biphasic insulin aspart 30 treatment in patients with type 2 diabetes poorly controlled on prior diabetes treatment: results from the PRESENT studyS K Sharma, M Al-Mustafa, S J Oh, et al.
The International Journal of Tuberculosis and Lung Disease : the Official Journal of the International Union Against Tuberculosis and Lung Disease|July 28, 1999
Comparative bioequivalence study of rifampicin and isoniazid combinations in healthy volunteersK A Padgaonkar, S N Revankar, A D Bhatt, et al.
The Journal of the Association of Physicians of India|March 7, 2009
Efficacy, safety and acceptability of biphasic insulin aspart 30 in Indian patients with type 2 diabetes: results from the PRESENT studyS K Sharma, S R Joshi, A Kumar, et al.
Pageof 1

Showing results (1-10 of 8) with videos related to

Sort By:
Pageof 1
Diabetes, Obesity & Metabolism|May 23, 2008
Biphasic insulin aspart 30 treatment improves glycaemic control in patients with type 2 diabetes in a clinical practice setting: Chinese PRESENT studyY Gao, X H Guo, J A Vaz, et al.
Diabetes, Obesity & Metabolism|May 16, 2008
Biphasic insulin aspart 30 in the treatment of elderly patients with type 2 diabetes: a subgroup analysis of the PRESENT Korea NovoMixstudyH C Jang, S R Lee, J A Vaz
The Journal of the Association of Physicians of India|March 7, 2001
Clinical relevance of reduced bioavailability of rifampicinA D Bhatt, J A Vaz, K A Padgaonkar
Diabetes, Obesity & Metabolism|November 18, 2003
Twice daily biphasic insulin aspart improves postprandial glycaemic control more effectively than twice daily NPH insulin, with low risk of hypoglycaemia, in patients with type 2 diabetesJ S Christiansen, J A Vaz, Z Metelko, et al.
Diabetes, Obesity & Metabolism|June 27, 2007
Adding biphasic insulin aspart 30 once or twice daily is more efficacious than optimizing oral antidiabetic treatment in patients with type 2 diabetesW M W Bebakar, C C Chow, K A Kadir, et al.
Current Medical Research and Opinion|January 25, 2008
Biphasic insulin aspart 30 treatment in patients with type 2 diabetes poorly controlled on prior diabetes treatment: results from the PRESENT studyS K Sharma, M Al-Mustafa, S J Oh, et al.
The International Journal of Tuberculosis and Lung Disease : the Official Journal of the International Union Against Tuberculosis and Lung Disease|July 28, 1999
Comparative bioequivalence study of rifampicin and isoniazid combinations in healthy volunteersK A Padgaonkar, S N Revankar, A D Bhatt, et al.
The Journal of the Association of Physicians of India|March 7, 2009
Efficacy, safety and acceptability of biphasic insulin aspart 30 in Indian patients with type 2 diabetes: results from the PRESENT studyS K Sharma, S R Joshi, A Kumar, et al.
Pageof 1